Many investors are wary of just how much of the new AbbVie's (NYSE: ABBV ) revenues are generated by one drug, Humira, and they are concerned what AbbVie will look like once Humira goes off its patent cliff in late 2016. In this video, however, Motley Fool health care bureau chief Brenton Flynn discusses how AbbVie is more than just Humira. Brenton talks about several of the drugs in the company's pipeline -- in spaces like hepatitis C, multiple sclerosis, Parkinson's disease, and endometriosis -- that could slow the revenue fall when Humira's patent expires.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.